ArticleNeuropsychiatric disease and treatment2025
Uncovering Potential Biomarkers and Constructing a Prediction Model Associated with Iron Metabolism in Parkinson's Disease.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolomic profiling uncovers diagnostic biomarkers and dysregulated pathways in Parkinson's disease.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a common neurodegenerative disorder. Iron metabolism abnormalities have been reported in PD patients and may contribute to disease pathogenesis. Our study aimed to explore key genes associated with iron metabolism in PD patients. Methods: Three datasets and iron metabolism-related genes (IMRGs) were collected from the public database, and the datasets were merged into a combined dataset. PD-related differentially expressed genes (DEGs) were obtained and intersected with IMRGs to acquire iron metabolism-related DEGs (IMRDEGs). Subsequently, the IMRDEGs were subjected to functional enrichment and ROC analyses. Finally, key genes were identified, followed by the construction and evaluation of a risk score model, drug prediction, and RT-qPCR analysis. Results: A total of 24 IMRDEGs were obtained. The AUC values of the 24 IMRDEGs ranged from 0.599 to 0.781. After logistic regression and the SVM analyses, a total of 10 key genes were identified, followed by the construction of the risk score model. The AUC value of the risk score model was 0.953, demonstrating good diagnostic value. The calibration curve and decision curve analysis showed that the risk score model has good predictive performance and clinical benefit for PD patients. Additionally, a total of 49 drugs were predicted. Conclusion: A total of 10 key genes were identified as potential biomarkers, and the risk score model was constructed for PD patients, exhibiting good diagnostic. This study may provide potential biomarkers for PD patients, promoting an understanding of the pathogenesis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.